← Back to Search

Genetic Testing for Parkinson's Disease (PDGENE Trial)

N/A
Waitlist Available
Led By Roy N Alcalay, MD, MS
Research Sponsored by Parkinson's Foundation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will test how well a genetic testing program works when offered to people with Parkinson's disease.

Who is the study for?
This trial is for people with a probable diagnosis of Parkinson's Disease who can consent to the study, complete surveys, and are willing to undergo genetic testing. They must understand the language of the informed consent. Those with blood cancers, recent bone marrow transplants or blood transfusions, or atypical parkinsonian disorders cannot participate.
What is being tested?
The trial is offering certified genetic testing for seven specific gene variants linked to Parkinson's Disease as part of clinical care. It aims to evaluate how feasible and satisfying this process is for participants.
What are the potential side effects?
Since this trial involves only genetic testing without any drugs or medical procedures, there are no direct physical side effects expected from participating in this study.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Feasibility of genetic testing and counseling
Impact Evaluation
Satisfaction Comparison
Secondary study objectives
Number of participants that enroll in precision medicine trials
Time it takes between first contact to the return of genetic test results

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Active Control
Group I: Site-Based Genetic CounselingActive Control1 Intervention
Participants randomized to this arm will receive genetic counseling for genetic results through the enrolling site.
Group II: Centralized Genetic CounselingActive Control1 Intervention
Participants randomized to this arm will receive genetic counseling for genetic results through a centralized genetic counseling group at Indiana University.

Find a Location

Who is running the clinical trial?

University of Rochester - CHeT/CTCCUNKNOWN
Parkinson's FoundationLead Sponsor
11 Previous Clinical Trials
1,028,902 Total Patients Enrolled
Fulgent LaboratoriesUNKNOWN

Media Library

Site-Based Genetic Counseling Clinical Trial Eligibility Overview. Trial Name: NCT04057794 — N/A
Parkinson's Disease Research Study Groups: Site-Based Genetic Counseling, Centralized Genetic Counseling
Parkinson's Disease Clinical Trial 2023: Site-Based Genetic Counseling Highlights & Side Effects. Trial Name: NCT04057794 — N/A
Site-Based Genetic Counseling 2023 Treatment Timeline for Medical Study. Trial Name: NCT04057794 — N/A
~321 spots leftby Nov 2025